Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description goes well beyond the read-only/idempotent annotations: it discloses graceful degradation when GLEIF/OpenFIGI is unavailable, that identifiers are source-labelled, that unresolved identifiers are returned explicitly under 'unresolved', and that ambiguous matches return 'figi_candidates' without asserting a single result. This richly characterizes behavior an agent could not infer from annotations or schema.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long and dense, but most sentences carry unique necessary information and the core instruction is front-loaded. The heavy use of nested parentheses makes it harder to scan, though the structure is justified by the tool's high complexity.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a read-only, two-parameter tool with no output schema, the description covers inputs, supported entity types, source mappings, failure behavior, ambiguity handling, and fallback guarantees. An agent has enough information to know when and how to call it and what to expect back.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is already 100%, but the description adds substantial meaning: accepted input forms (ticker, CIK, ISIN, name), the distinction between implied ticker maps and name search, non-equity instrument resolution, and the critical warning to pass only the entity name and never the full noun phrase. This materially improves parameter understanding.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description names a specific verb and resource — 'resolve a user-spoken NAME to the canonical/official identifiers' — and enumerates supported types (company, drug). It clearly distinguishes itself from sibling tools by positioning itself as the first stop when a name needs to become an ID.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly says 'Use FIRST whenever you have a name but need an ID,' which gives a strong usage condition. It does not name alternative tools or give when-not-to-use guidance, but the context and examples make the intended invocation clear.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Multiple tools overlap heavily: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded are nearly identical routers, the six polymarket tools cover similar prediction-market territory with fuzzy boundaries, and the deps.dev tools (package/version/dependencies/query/scan_dependency) all deliver dependency metadata. An agent would frequently need the lengthy descriptions to pick the right one.

Naming Consistency2/5

Tool names mix several conventions: noun-only names (package, version, query, project, dependencies), verb_noun names (scan_dependency, validate_claim, resolve_entity), and family-prefixed names (ask_pipeworx_*, polymarket_*, pipeworx_*). There is no single consistent pattern across the set.

Tool Count2/5

With 36 tools, the server is well past the 'heavy' threshold. The scope is also sprawling: general data querying, dependency lookup, memory management, subscriptions, prediction markets, claim verification, and AI-visibility scanning. Many tools could be consolidated or moved to separate servers.

Completeness3/5

The tool set is individually broad and covers many workflows, but the server's stated identity ('Deps Dev') does not match the dominant Pipeworx data surface, creating an unclear core purpose. Within the dependency sub-domain it is fairly complete, and the data-research workflows have decent coverage, but gaps like subscription updates and true deps.dev ecosystem coverage suggest the surface is improvised.